Skip to main content
SpringerLink
Log in
Book cover

Serous Effusions pp 75–85Cite as

Breast Carcinoma

  • Chapter
  • First Online:

  • 521 Accesses

Abstract

In this chapter we discuss the main morphological aspects of breast carcinoma in serous effusions in the different types of cytological preparations. The differential diagnosis with reactive mesothelial cells, malignant mesothelioma, and other types of adenocarcinoma is carefully approached with a description of the main morphological aspects important for this differentiation. In the section devoted to complementary techniques, the main antibodies used for the diagnosis, as well as for the study of factors predictive to therapy, are discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev. 2015;24:1495–506.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  Google Scholar 

  3. Fentiman IS, Millis R, Sexton S, Hayward JL. Pleural effusion in breast cancer: a review of 105 cases. Cancer. 1981;47:2087–92.

    Article  CAS  PubMed  Google Scholar 

  4. Raju RN, Kardinal CG. Pleural effusion in breast carcinoma: analysis of 122 cases. Cancer. 1981;48:2524–7.

    Article  CAS  PubMed  Google Scholar 

  5. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer. 1995;76:1377–87.

    Article  CAS  PubMed  Google Scholar 

  6. Buck M, Ingle JN, Giuliani ER, Gordon JR, Therneau TM. Pericardial effusion in women with breast cancer. Cancer. 1987;60:263–9.

    Article  CAS  PubMed  Google Scholar 

  7. DiBonito L, Falconieri G, Colautti I, Bonifacio D, Dudine S. The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 1993;37:483–8.

    PubMed  CAS  Google Scholar 

  8. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer. 1985;56:905–9.

    Article  CAS  PubMed  Google Scholar 

  9. Pokieser W, Cassik P, Fischer G, Vesely M, Ulrich W, Peters-Engl C. Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor. Breast Cancer Res Treat. 2004;83:139–42.

    Article  CAS  PubMed  Google Scholar 

  10. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988;62:2226–33.

    Article  CAS  PubMed  Google Scholar 

  11. DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest. 1997;112(4 Suppl):291S–5S.

    Article  PubMed  Google Scholar 

  12. Geisinger KR, Stanley MW, Raab SS, Silverman JF, Abati A, editors. Modern cytopathology. Philadelphia: Churchill Livingstone; 2004.

    Google Scholar 

  13. Bedrossian CWM, editor. Malignant effusions. A multimodal approach to cytologic diagnosis. New York: Igaku-Shoin; 1994.

    Google Scholar 

  14. Shidham VB, Atkinson BF. Cytopathologic diagnosis of serous fluids. London: Elsevier; 2007.

    Google Scholar 

  15. Pleural NB. peritoneal and pericardial effusions. In: Bibbo M, Wilbur D, editors. Comprehensive cytopathology. Philadelphia: Elsevier; 2008. p. 515–78.

    Google Scholar 

  16. Shidham VB, Falzon M. Serous effusions. In: Gray W, Kocjan G, editors. Diagnostic cytopathology. London: Churchill Livingstone; 2010. p. 115–78.

    Chapter  Google Scholar 

  17. Rappa G, Lorico A. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line. Exp Cell Res. 2010;316:1576–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Danner DE, Gmelich JTA. comparative study of tumor cells from metastatic carcinoma of the breast in effusions. Acta Cytol. 1975;19:509–18.

    PubMed  CAS  Google Scholar 

  19. Goldberg S, Rey G, Luce D, Gilg Soit Ilg A, Rolland P, Brochard P, Imbernon E, Goldberg M. Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates. Occup Environ Med. 2010;67:417–21.

    Article  PubMed  Google Scholar 

  20. Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol. 2009;17:202–6.

    Article  CAS  PubMed  Google Scholar 

  21. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–94.

    Article  CAS  PubMed  Google Scholar 

  22. Yan Z, Gidley J, Horton D, Roberson J, Eltoum IE, Chhieng DC. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Diagn Cytopathol. 2009;37:475–8.

    Article  CAS  PubMed  Google Scholar 

  23. Fiel MI, Cernaianu G, Burstein DE, Batheja N. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol. 1996;40:637–41.

    Article  CAS  PubMed  Google Scholar 

  24. Wang LJ, Greaves WO, Sabo E, et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol. 2009;17:505–11.

    Article  CAS  PubMed  Google Scholar 

  25. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654–61.

    Article  CAS  PubMed  Google Scholar 

  26. Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G, Yub Gong G, Ro JY, Jim Zhai Q. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol. 2009;2:384–9.

    PubMed  CAS  Google Scholar 

  27. Barghava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103–13.

    Article  CAS  Google Scholar 

  28. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathologic analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20:208–14.

    Article  CAS  PubMed  Google Scholar 

  29. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker mammaglobin. Diagn Mol Pathol. 2010;19:92–8.

    Article  PubMed  Google Scholar 

  30. Shield PW, Papadimos DJ, Walsh MD. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol. 2014;122:307–12.

    Article  CAS  PubMed  Google Scholar 

  31. Lew M, Pang JC, Jing X, Fields KL, Roh MH. Young investigator challenge: the utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Cancer Cytopathol. 2015;123:576–81.

    Article  CAS  PubMed  Google Scholar 

  32. El Hag MI, Ha J, Farag R, El Hag AM, Michael CW. Utility of GATA-3 in the work-up of breast adenocarcinoma and its differential diagnosis in serous effusions: a cell-block microarray study. Diagn Cytopathol. 2016;44:731–6.

    Article  PubMed  Google Scholar 

  33. Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F. Expression of FOXA1 and GATA3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009;11:R40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Dabbs DJ, Landreneau RJ, Liu Y, Raab SS, Maley RH, Tung MY, Silverman JF. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403–5.

    Article  PubMed  Google Scholar 

  35. Shabaik A, Lin G, Peterson M, Hasteh F, Tipps A, Datnow B, Weidner N. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol. 2011;39:328–32.

    Article  PubMed  Google Scholar 

  36. Schlüter B, Gerhards R, Strumberg D, Voigtmann R. Combined detection of HER2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136:1389–400.

    Article  CAS  PubMed  Google Scholar 

  37. Arihiro K, Oda M, Ogawa K Tominaga K, Kaneko Y, Shimizu T, Matsumoto S, Oda M, Kurita Y, Taira Y. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples. Jpn J Clin Oncol. 2013;43:55–62.

    Article  PubMed  Google Scholar 

  38. Nakayama Y, Nakagomi H, Omori M, Inoue M, Takahashi K, Maruyama M, Takano A, Furuya K, Amemiya K, Ishii E, Oyama T. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer. Breast Cancer. 2016;23:633–9.

    Article  PubMed  Google Scholar 

  39. Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin Cancer Res. 2004;10:7335–46.

    Article  CAS  PubMed  Google Scholar 

  40. Konstantinovsky S, Smith Y, Zilber S, Tuft Stavnes H, Becker AM, Nesland JM, Reich R, Davidson B. Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol. 2010;2010:969084.

    Article  CAS  PubMed  Google Scholar 

  41. Davidson B, Dong HP, Holth A, Berner A, Risberg B. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. Breast J. 2008;14:476–82.

    Article  PubMed  Google Scholar 

  42. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MTP, Bassarova A, Kvalheim G, Nesland JM, Reich R. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 2006;102:453–61.

    Article  CAS  PubMed  Google Scholar 

  43. Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B. Netrin 4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. Diagn Cytopathol. 2011;39:562–6.

    Article  PubMed  Google Scholar 

  44. Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IM, Wang TL. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2011;15:535–44.

    Article  CAS  PubMed  Google Scholar 

  45. Davidson B, Stavnes HT, Nesland JM, Wohlschlaeger J, Yang Y, Shih IM, Wang TL. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Hum Pathol. 2012;43:684–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Oncology, Medical Faculty of Porto University, Porto, Portugal

    Fernando Schmitt M.D., Ph.D., F.I.A.C.

  2. Molecular Pathology Unit, Institute of Pathology and Molecular Immunology of Porto University, IPATIMUP, Porto, Portugal

    Fernando Schmitt M.D., Ph.D., F.I.A.C.

  3. International Academy of Cytology, Freiburg, Germany

    Fernando Schmitt M.D., Ph.D., F.I.A.C.

  4. Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    Ben Davidson M.D., Ph.D.

  5. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    Ben Davidson M.D., Ph.D.

Authors
  1. Fernando Schmitt M.D., Ph.D., F.I.A.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ben Davidson M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Schmitt M.D., Ph.D., F.I.A.C. .

Editor information

Editors and Affiliations

  1. Department of Pathology, The Norwegian Radium Hospital Oslo University Hospital , Oslo, Norway

    Ben Davidson

  2. Department of Pathology, School of Medicine, Koç University, Istanbul, Turkey

    Pinar Firat

  3. UH Cleveland Medical Center, Case Western Reserve University, UH Clevel and Medical Center, Cleveland, Ohio, USA

    Claire W. Michael

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schmitt, F., Davidson, B. (2018). Breast Carcinoma. In: Davidson, B., Firat, P., Michael, C. (eds) Serous Effusions. Springer, Cham. https://doi.org/10.1007/978-3-319-76478-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76478-8_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76477-1

  • Online ISBN: 978-3-319-76478-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation